Iovance Biotherapeutics to Present at Two Upcoming September Conferences
September 05 2017 - 8:00AM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that it will webcast a business overview and update by Dr. Maria
Fardis, PhD, MBA, Chief Executive Officer of Iovance
Biotherapeutics at the following upcoming investor conferences:
- Rodman & Renshaw 19th Annual Global Investment
Conference in New York, NY on Monday, September 11, 2017
at 11:40 a.m. ET
- 2017 Cantor Fitzgerald Global Healthcare
Conference in New York, NY on Monday, September 25, 2017
at 8:00 a.m. ET
A live audio webcast of both presentations will be available by
visiting the Investors section Iovance Biotherapeutics' website
at http://ir.iovance.com/. A replay of the webcast will be
archived on Iovance Biotherapeutics’ website for 30 days following
the presentation.
About Iovance Biotherapeutics, Inc. Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology company
focused on the development of cancer immunotherapy products for the
treatment of various cancers. The Company's lead product candidate
is an adoptive cell therapy using tumor-infiltrating lymphocyte
(TIL) technology being investigated for the treatment of patients
with metastatic melanoma, recurrent and/or metastatic squamous cell
carcinoma of the head and neck and recurrent and metastatic or
persistent cervical cancer. For more information, please
visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024